Title: Hepatocyte Growth Factor Gene Therapy Attenuates Liver Fibrosis Induced by Bile Duct Ligation
Abstract:Objective: To exam the therapeutic efficacy of hepatocyte growth factor (HGF) gene therapy in a bile duct ligation liver fibrosis model. Methods: Male CD-1 mice were randomized into 3 groups, the norm...Objective: To exam the therapeutic efficacy of hepatocyte growth factor (HGF) gene therapy in a bile duct ligation liver fibrosis model. Methods: Male CD-1 mice were randomized into 3 groups, the normal group merely underwent surgery without bile duct ligation, the other 2 groups underwent bile duct ligation, received biweekly injection of pCMV-HGF (1μg/g), or pcDNA3 respectively. The severity of liver fibrosis was evaluated at 3 months after bile duct ligation. Results: HGF gene therapy markedly attenuated collagen deposition, as showed by Masson-Trichrome staining and immunofluorescence staining of collagen Ⅰ,Ⅲ in the peri-biliary region. Compared with pcD-NA3 treated group, HGF gene therapy could significantly suppress hepatic myofibroblast activation, which was demonstrated by reduction of α-SMA expression (0.32 ± 0.05 vs. 0. 84 ± 0.14, P0.05), decrease the hydroxyproline content (0.48 ± 0.04 μg/mg vs. 1.37 ± 0.06μg/mg, P0.05), suppress expression of transforming growth factor-pi (0.69 ± 0.11 vs.1.31 ± 0.23, P0.01). Conclusion: It suggested that HGF gene therapy could attenuate liver fibrosis induced by bile duct ligation and HGF may provide an effective therapeutic strategy for the treatment of chronic liver fibrosis.Read More
Publication Year: 2005
Publication Date: 2005-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot